Physician profile
Stephanie Roach
NPI 1275820599
$3,390.28
in general payments reported to CMS, 2019-2025
33 companies · $673 in 2025
The $673 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,018 · 2022: $636 · 2023: $653 · 2024: $411 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $714.61 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $427.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $413.13 | 2021-2025 | |
| Abbott Laboratories | $344.67 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $181.93 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Amarin Pharma, INC. | $134.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.10 | 2021-2025 | |
| Amgen INC. | $107.82 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $95.07 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $86.71 | 2021-2022 | |
| Esperion Therapeutics, INC. | $85.24 | 2021-2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.97 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $67.38 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $66.55 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.54 | 2022-2023 | Eliquis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.15 | 2023-2025 | Veozah |
| Alkermes, INC. | $36.39 | 2023-2025 | Aristada, Lybalvi |
| Exact Sciences Corporation | $34.45 | 2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $33.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.97 | 2021 | |
| Eisai INC. | $29.96 | 2021 | |
| Viatris Specialty LLC | $23.81 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $21.00 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $20.51 | 2025 | Inspire |
| Inogen, INC. | $18.08 | 2023 | Inogen At Home Stationary Concentrator |
| Biohaven Pharmaceutical Holding Company LTD. | $17.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.30 | 2021 | |
| Mylan Specialty L.P. | $15.62 | 2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $14.64 | 2025 | Rexulti |
| Upsher-Smith Laboratories LLC | $14.40 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.47 | 2021 | |
| Horizon Therapeutics Plc | $12.99 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.